Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Gsk Plc ADR (GSK)

Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 79,228,112
  • Shares Outstanding, K 2,063,232
  • Annual Sales, $ 40,095 M
  • Annual Income, $ 3,291 M
  • EBIT $ 6,040 M
  • EBITDA $ 9,300 M
  • 60-Month Beta 0.51
  • Price/Sales 1.95
  • Price/Cash Flow 6.75
  • Price/Book 4.52

Options Overview Details

View History
  • Implied Volatility 25.66% ( -0.90%)
  • Historical Volatility 28.22%
  • IV Percentile 57%
  • IV Rank 45.92%
  • IV High 50.40% on 04/08/25
  • IV Low 4.64% on 08/29/24
  • Put/Call Vol Ratio 0.08
  • Today's Volume 2,210
  • Volume Avg (30-Day) 5,293
  • Put/Call OI Ratio 0.55
  • Today's Open Interest 108,935
  • Open Int (30-Day) 128,159

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 1.09
  • Number of Estimates 4
  • High Estimate 1.20
  • Low Estimate 1.00
  • Prior Year 1.09
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.79 +7.28%
on 04/21/25
40.38 -4.90%
on 04/30/25
+2.47 (+6.87%)
since 04/17/25
3-Month
32.38 +18.59%
on 04/09/25
40.81 -5.89%
on 03/10/25
+1.44 (+3.90%)
since 02/20/25
52-Week
31.72 +21.08%
on 01/14/25
45.79 -16.15%
on 05/22/24
-6.19 (-13.88%)
since 05/20/24

Most Recent Stories

More News
Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now?

Gilead Sciences, Inc. GILD and GSK GSK are pioneers in the human immunodeficiency virus (HIV) treatment space.Gilead Sciences is a dominant player in the HIV market with market-leading treatments. HIV...

GILD : 109.11 (+2.78%)
GSK : 38.40 (+1.16%)
Why These 4 Women-Run Companies Deserve a Spot in Your Portfolio?

An updated edition of the March 27, 2025, article.For years, corporate leadership has largely been male-dominated, but that dynamic is shifting. Increasingly, women-run companies are emerging as powerhouses...

KO : 71.69 (-0.33%)
GM : 50.21 (+0.36%)
PGR : 285.63 (-0.91%)
GSK : 38.40 (+1.16%)
HSY : 155.70 (-0.54%)
DIS : 112.36 (-0.27%)
The Zacks Analyst Blog Highlights Bayer, Novo Nordisk, GSK, Merck and AbbVie

For Immediate ReleaseChicago, IL – May 19, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

BAYRY : 6.6700 (+2.62%)
NVO : 68.20 (+1.76%)
MRK : 77.97 (+0.96%)
ABBV : 184.85 (-0.46%)
GSK : 38.40 (+1.16%)
Pharma Stock Roundup: BAYRY Q1 Earnings, NVO & GSK's New Deals

This week, Bayer BAYRY announced first-quarter 2025 results. Novo Nordisk NVO and GSK plc GSK announced licensing deals with smaller biotechs. The FDA granted approval to Merck’s MRK drug, Welireg, for...

BAYRY : 6.6700 (+2.62%)
NVO : 68.20 (+1.76%)
MRK : 77.97 (+0.96%)
ABBV : 184.85 (-0.46%)
GSK : 38.40 (+1.16%)
Moderna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1

Moderna MRNA kicked off 2025 with mixed first-quarter results. While its streamlining efforts improved bottom-line numbers, the steep decline in revenues raises concerns.While sales of its COVID-19 vaccine...

MRK : 77.97 (+0.96%)
MRNA : 27.99 (+6.06%)
GSK : 38.40 (+1.16%)
PFE : 23.52 (+2.26%)
Moderna Beats on Q1 Earnings, Lags on Revenues, Focuses on Cost Cuts

Moderna MRNA incurred a loss of $2.52 per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $2.92. In the year-ago period, the company had reported a loss of $3.07.Total...

MRK : 77.97 (+0.96%)
MRNA : 27.99 (+6.06%)
GSK : 38.40 (+1.16%)
PFE : 23.52 (+2.26%)
Should You Buy, Sell or Hold GILD Stock Post Q1 Earnings Miss?

Last week, biotech bigwig Gilead Sciences, Inc. GILD reported lower-than-expected first-quarter 2025 results. Adjusted earnings per share (EPS) of $1.81 missed the Zacks Consensus Estimate by a penny....

MRK : 77.97 (+0.96%)
GILD : 109.11 (+2.78%)
GSK : 38.40 (+1.16%)
Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?

Biotech bigwig Gilead Sciences, Inc. GILD  is scheduled to report first-quarter 2025 results on April 24, after market close. The Zacks Consensus Estimate for sales and earnings is pegged at $6.83 billion...

MRK : 77.97 (+0.96%)
GILD : 109.11 (+2.78%)
GSK : 38.40 (+1.16%)
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease

ALEC : 1.3700 (+7.87%)
GSK.LN : 1,424.000 (+0.60%)
GSK : 38.40 (+1.16%)
PFE Secures EU Nod for Expanded Use of RSV Vaccine Abrysvo

Pfizer PFE announced that the European Commission (“EC”) has granted marketing authorization to expand the use of its RSV vaccine, Abrysvo. The vaccine has been approved for the prevention of lower...

MRNA : 27.99 (+6.06%)
GSK : 38.40 (+1.16%)
PFE : 23.52 (+2.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 39.04
2nd Resistance Point 38.75
1st Resistance Point 38.57
Last Price 38.40
1st Support Level 38.10
2nd Support Level 37.81
3rd Support Level 37.63

See More

52-Week High 45.79
Fibonacci 61.8% 40.42
Fibonacci 50% 38.75
Last Price 38.40
Fibonacci 38.2% 37.09
52-Week Low 31.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
OSZAR »